The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2 ...

The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2 ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

CRISPR Therapeutics has two next generation approaches ... developed targeted conditioning program, an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical studies.

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

New strategies promise to streamline workflows, conserve consumables, increase productivity, and enhance reproducibility.

Collectively, emerging technologies are creating an unstable world, where we don’t clearly understand what national security ...

The tool segment is segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, chassis organisms ... range of products for the synthetic biology industry, such as CRISPR & Gene ...